Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway

19 Dec 2023

Abstract excerpt

Here, we investigated the detailed molecular oncogenic mechanisms of a novel receptor tyrosine kinase (RTK) fusion, KLC1-ROS1, with an adapter molecule, KLC1, and an RTK, ROS1, discovered in pediatric glioma, and we explored a novel therapeutic target for glioma that possesses oncogenic RTK fusion. When wild-type ROS1 and KLC1-ROS1 fusions were stably expressed in the human glioma cell lines A172 and U343MG,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cytokine Signaling Pathways and Interactions
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38201436
DOI: 10.3390/cancers16010009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT PathwayPMID 38201436Read ↗

Molecular pathways: ROS1 fusion proteins in cancer.Semantic proximity Read ↗

<i>ROS1</i> Fusions in Cancer: A ReviewSemantic proximity Read ↗

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in GliomaSemantic proximity Read ↗

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion ProteinsSemantic proximity Read ↗

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.Semantic proximity Read ↗

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.Semantic proximity Read ↗

ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.Semantic proximity Read ↗

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma typesSemantic proximity Read ↗

Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.Semantic proximity Read ↗

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitorsSemantic proximity Read ↗

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancerSemantic proximity Read ↗

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.